Clinical Efficacy of atezolizumab (atezo) in PD-L1 subgroups defined by SP142 and 22C3 IHC assays in 2L+ NSCLC: Results from the randomized OAK study

K Park,H Koeppen,A Rittmeyer,Ps Hegde,A Sandler,Fr Hirsch,D Gandara,S Gadgeel,M Kowanetz,F Barlesi,W Zou,M Ballinger,M Mccleland,Km Kerr

doi:10.1055/s-0037-1619252

Clinical Efficacy of atezolizumab (atezo) in PD-L1 subgroups defined by SP142 and 22C3 IHC assays in 2L+ NSCLC: Results from the randomized OAK study

K Park, H Koeppen + Show 12 more

https://doi.org/10.1055/s-0037-1619252

Copy DOI

Journal: Pneumologie	Publication Date: Feb 21, 2018
Citations: 1

Affiliation: Sungkyunkwan University, University of Colorado Anschutz Medical Campus, University of California, Davis, University of Michigan–Ann Arbor, Aberdeen Royal Infirmary

#SP142 IHC #SP142 Assays + Show 5 more

Abstract
Full-Text PDF
Similar Papers

Abstract

Clinical Efficacy of atezolizumab (atezo) in PD-L1 subgroups defined by SP142 and 22C3 IHC assays in 2L+ NSCLC: Results from the randomized OAK study

Full Text

Paper version not known

Open DOI Link

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Similar Papers

Paper Title

Journal

Date

Author

View more papers

More From: Pneumologie

Paper Title

Journal

Date

Author

View more papers

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.